Marketing of personalized cancer care on the web: An analysis of internet websites

Journal of the National Cancer Institute

Volumn 107, Issue 5, 2015, Pages

  Gray, Stacy W ^a,b,c   Cronin, Angel ^a   Bair, Elizabeth ^a   Lindeman, Neal ^b,c   Viswanath, Vish ^a,d   Janeway, Katherine A ^a,b,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CENTER; CANCER SCREENING; CANCER THERAPY; DOCTOR PATIENT RELATION; GENETIC SCREENING; GERM LINE; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; INTERNET; ONCOLOGY; PERSONALIZED MEDICINE; PHYSICIAN; PRIORITY JOURNAL; SOCIAL MARKETING; WEB BROWSER; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GENETICS; METABOLISM; NEOPLASMS; NUCLEOTIDE SEQUENCE; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

DNA MUTATIONAL ANALYSIS; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; INTERNET; MARKETING OF HEALTH SERVICES; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84925761378     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv030     Document Type: Article

References (33)

1. Hudson KL. Genomics, health care, and society. N Engl J Med. 2011;365(11):1033-1041.
2. Abel GA, Nuefeld EJ, Sorel M, Weeks JC. Direct-to-consumer advertising for bleeding disorders: A content analysis and expert evaluation of advertising claims. J Thromb Haemost. 2008;6(10):1680-1684.
3. Lovett KM, Liang BA, Mackey TK. Risks of Online Direct-to-Consumer Tumor Markers for Cancer Screening. J Clin Oncol. 2012;30(13):1411-1414.
4. Larson RJ, Schwartz LM, Woloshin S, Welch HG. Advertising by academic medical centers. Arch Intern Med. 2005;165(6):645-651.
5. Lovett KM, Liang BA. Risks of online advertisement of direct-to-consumer thermography for breast cancer screening. Nat Rev Cancer. 2011;11(12):827-828.
6. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.
7. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med. 2009;11(1):3-14.
8. StataCorp LP. Stata Statistical Software: Release 11. College Station, TX; 2009.
9. Wilkinson L, Urbanek S. Venneuler: Venn and Euler Diagrams. R package version; 2011.
10. Mouchawar J, Laurion S, Ritzwoller DP, Ellis J, Kulchak-Rahm A, Hensley-Alford S. Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: reactions from women and their physicians in a managed care organization. Am J Manag Care. 2005;11(10):601-608.
11. Mouchawar J, Hensley-Alford S, Laurion S, et al. Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: A naturally-occurring experiment. Genet Med. 2005;7(3):191-197.
12. Abel GA, Burstein HJ, Hevelone ND, Weeks JC. Cancer-Related Direct-to-Consumer Advertising: Awareness, Perceptions, and Reported Impact Among Patients Undergoing Active Cancer Treatment. J Clin Oncol. 2009;27(25):4182-4187.
13. Green RC, Farahany NA. Regulation: The FDA is overcautious on consumer genomics. Nature. 2014;505(7483):286-287.
14. Heger M. As Revenues Continue to Rise, Foundation Medicine Looks to Expand Test, Enable Outcomes Monitoring. genomewebcom. Available at: http://www. genomeweb. com/sequencing/revenues-continue-rise-foundation-medicine-looks-expand-test-enable-outcomes-mon. Accessed February 26, 2014.
15. Schrag D. American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays. J Clin Oncol. 2004;22(17):3631-3638.
16. Burstein HJ, Mangu PB, Somerfield MR, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays. J Clin Oncol. 2011;29(24):3328-3330.
17. Illes J, Kann D, Karetsky K, et al. Advertising, patient decision making, and self-referral for computed tomographic and magnetic resonance imaging. Arch Intern Med. 2004;164(22):2415-2419.
18. Lachance CR, Erby LAH, Ford BM, Allen VC Jr, Kaphingst KA. Informational content, literacy demands, and usability of websites offering health-related genetic tests directly to consumers. Genet Med. 2010;12(5):304-312.
19. Caulfield T, McGuire AL. Direct-to-consumer genetic testing: perceptions, problems, and policy responses. Annu Rev Med. 2012;63:23-33.
20. Einsiedel EF, Geransar R. Framing genetic risk: trust and credibility markers in online direct-to-consumer advertising for genetic testing. New Genetics and Society. 2009;28(4):339-362.
21. U S Government Accountability Office HGG. GAO-06-977T Nutrigenetic Testing: Tests Purchased from Four Web Sites Mislead Consumers. 2006:1-27.
22. U S Government Accountability Office HGG. GAO-10-847T Direct-To-Consumer Genetic Tests: Misleading Test Results Are Further Complicated by Deceptive Marketing and Other Questionable Practices. 2010:1-33.
23. Downing NS, Ross JS. Innovation, Risk, and Patient Empowerment. JAMA. 2014;311(8):793-794.
24. Gutierrez A. 23andMe, Inc. FDA Warning Letter, 11/22/2013. 2014:1-3. Available at: http://www. fda. gov/iceci/enforcementactions/warningletters/2013/ucm376296. htm.
25. Annas GJ, Elias S. 23andMe and the FDA. N Engl J Med. 2014;370(23):2248-2249.
26. Aspinall M, Au SM, Billings P, et al. US system of oversight for genetic testing: A report from the Secretary's Advisory Committee on Genetics, Health and Society. Personalized Medicine. 2008;5(5):521-528.
27. The Food and Drug Administration. Draft guidance for industry, food and drug administration staff and clinical laboratories: FDA notification and medical device reporting for laboratory developed tests (LDTs). fdagov. Available at: http://www. fda. gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM416684. pdf. Accessed October 10, 2014.
28. Wilkes MS, Bell RA, Kravitz RL. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff (Millwood). 2000;19(2):110-128.
29. Teutsch S. Genetics Education and Training. obaodnihgov. 2011:1-211. Available at: http://oba. od. nih. gov/oba/SACGHS/reports/SACGHS-education- report-2011. pdf. Accessed December 16, 2011.
30. Gray SW, Abel GA. Update on Direct-to-Consumer Marketing in Oncology. J Oncol Pract. 2012;8(2):124-127.
31. Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014;32(13):1317-1323.
32. Selkirk CG, Weissman SM, Anderson A, Hulick PJ. Physicians' preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers. 2013;17(3): 219-225.
33. Bellcross CA, Kolor K, Goddard KAB, Coates RJ, Reyes M, Khoury MJ. Awareness and Utilization of BRCA1/2 Testing Among U. S. Primary Care Physicians. AMEPRE. 2011;40(1):61-66.